Please login to the form below

Not currently logged in
Email:
Password:

Repligen

This page shows the latest Repligen news and features for those working in and with pharma, biotech and healthcare.

Biogen buys into Ionis' nusinersen after positive phase III trial

Biogen buys into Ionis' nusinersen after positive phase III trial

Other companies working on therapies for SMA includeand Pfizer/Repligen.

Latest news

  • Pfizer acquires spinal muscular atrophy research programme Pfizer acquires spinal muscular atrophy research programme

    Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials carried out by Repligen in the first quarter of 2013.

  • Oncology bias in pharma deals

    112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.

  • Repligen bipolar drug fails in study

    An oral form of uridine being developed by Repligen as a potential treatment for bipolar depression failed to show efficacy in a late-stage clinical trial. ... However, Repligen noted that a preliminary analysis indicates that in the 50 patients in the

  • State of mind

    RG 2417. Repligen. Bipolar disorder. Anticonvulsants. Anticonvulsants, such as lamotrigine and valproic acid, have been found useful as mood stabilisers, preventing the extremes of mania and depression in patients with bipolar ... RG 2417 (Repligen) is a

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    Repligen announced the signature of an exclusive worldwide licensing agreement with Pfizer to advance Repligen's spinal muscular atrophy (SMA) programme. ... Repligen will receive up to $70m from Pfizer with an upfront payment of $5m and future

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics